14,067 Shares in CRISPR Therapeutics AG $CRSP Acquired by Entropy Technologies LP

Entropy Technologies LP purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 14,067 shares of the company’s stock, valued at approximately $669,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Mcguire Capital Advisors Inc. bought a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $25,000. Ramirez Asset Management Inc. bought a new position in shares of CRISPR Therapeutics during the fourth quarter worth $26,000. Rothschild Investment LLC grew its stake in CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after acquiring an additional 502 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its stake in CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after acquiring an additional 382 shares in the last quarter. Finally, Oakworth Capital Inc. purchased a new position in CRISPR Therapeutics during the fourth quarter valued at $34,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Naimish Patel sold 3,786 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the transaction, the insider owned 19,357 shares of the company’s stock, valued at approximately $1,076,636.34. This trade represents a 16.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 5.20% of the company’s stock.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $47.64 on Thursday. The company has a market cap of $4.59 billion, a price-to-earnings ratio of -7.66 and a beta of 1.71. The firm’s fifty day moving average is $52.60 and its 200 day moving average is $52.49. The company has a quick ratio of 17.96, a current ratio of 17.97 and a debt-to-equity ratio of 0.32. CRISPR Therapeutics AG has a 52-week low of $44.12 and a 52-week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The business had revenue of $1.46 million during the quarter. Sell-side analysts forecast that CRISPR Therapeutics AG will post -4.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on CRSP shares. Wall Street Zen cut shares of CRISPR Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, July 5th. Citigroup restated a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Wednesday, July 22nd. Morgan Stanley set a $60.00 price objective on CRISPR Therapeutics and gave the company an “equal weight” rating in a research report on Thursday, June 11th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, July 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $67.78.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.